Consensus Novartis AG Nyse

Equities

NVS

US66987V1098

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
96.73 USD +0.89% Intraday chart for Novartis AG +0.68% -4.20%

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History of analyst recommendation changes

752ab736.57P1Gq9PDjoivqAajil9kP8JkkxRMV-mrRnjCfuTG0A.hvimfso6bA9Lk8RLx2Q2p5FP1BULUiv06n7bMLThVBOAhoZewSRgC0yJzw~bdb93ca8222f8d157c0dbc4ea65c480f
NOVARTIS AG : Berenberg remains Neutral ZD
NOVARTIS AG : Buy rating from Deutsche Bank ZD
BMO Capital Initiates Novartis at Market Perform Rating With $114 Price Target MT
NOVARTIS : Novartis on course to set new highs Alphavalue
Moody's Lifts Novartis' Ratings, Outlook on Solid Operating Performance MT
Novartis' Midterm Sales Growth Prospects Limited as Patent Expirations Loom, Berenberg Says MT
This time it's for real Our Logo
NOVARTIS AG : Receives a Buy rating from Deutsche Bank ZD
NOVARTIS : UBS remains Buy on the stock CF
NOVARTIS AG : Gets a Neutral rating from JP Morgan ZD
Swiss Market Index Blinks Red Amid Renewed Rate Jitters MT
NOVARTIS AG : Barclays remains a Sell rating ZD
North American Morning Briefing : Rate Doubts Keep Pressure on Stocks; More Earnings in Focus DJ
European Midday Briefing : Stocks Higher But Gains Capped On Rate Doubts DJ
NOVARTIS AG : Buy rating from UBS ZD
NOVARTIS AG : Jefferies reiterates its Buy rating ZD
NOVARTIS AG : Deutsche Bank remains its Buy rating ZD
NOVARTIS AG : Receives a Buy rating from DZ Bank ZD
Which Jerome will we get? Our Logo
NOVARTIS : Strong finish to 2023; healthy 2024 guidance; Q4 miss not a worry Alphavalue
NOVARTIS AG : UBS reiterates its Buy rating ZD
NOVARTIS AG : Receives a Buy rating from Jefferies ZD
NOVARTIS AG : UBS reaffirms its Buy rating ZD
Can Novartis dethrone Roche as the largest Swiss Pharma? Alphavalue
UBS Upgrades Novartis to Buy from Neutral, Boosts PT MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
95.72 USD
Average target price
108.7 USD
Spread / Average Target
+13.52%
High Price Target
128.1 USD
Spread / Highest target
+33.86%
Low Price Target
82.36 USD
Spread / Lowest Target
-13.95%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

BERENBERG Kerry Holford
DEUTSCHE BANK RESEARCH Emmanuel Papadakis
BMO Capital
alphavalue Abhishek Raval
JPMORGAN Richard Vosser
BARCLAYS Emily Field
UBS Matthew Weston
JEFFERIES Peter Welford
DZ BANK Elmar Kraus
Kepler Capital Markets
Societe Generale
Redburn
Stifel Nicolaus
BNP Paribas
MORGAN STANLEY Mark Purcell
Barrington Research
Credit Suisse
International Strategy & Investment Group
Morningstar
ODDO BHF
GOLDMAN SACHS Keyur Parekh
DA Davidson
Zacks Equity Research
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Berenberg Bank
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER Eric Le Berrigaud
LIBERUM CAPITAL Graham Doyle
BANK OF AMERICA (BOFA) Graham Parry
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings